Kungsbacka

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.

This research aims to develop and improve a decision support system for patients experiencing chest pain before they reach the hospital. It focuses on evaluating how well a machine learning model can assist emergency medical services in assessing these patients. The study addresses the challenge of safely directing patients to the right level of care, balancing timely treatment for serious conditions like heart attacks or strokes with avoiding unnecessary hospital visits that may cause delays or overcrowding. Participants will be asked questions at the scene about their medical history and pain details, and a blood sample for troponin and glucose will be taken and analyzed immediately. The study collects routine medical record data and scene measurements to validate and further develop the decision support model. Participants will continue to receive standard care according to guidelines, typically transport to an emergency department if needed. Throughout the study, researchers will monitor clinical outcomes including time-sensitive conditions, deaths within seven days, and adverse events within 72 hours after ambulance service inclusion. Data from the initial assessment, blood tests, and medical records will help evaluate the models predictive performance. The study is observational, and participant involvement includes answering questions and consenting to data and sample collection. The total duration extends from emergency contact through hospital discharge and follow-up periods up to 100 days.

Researchers are evaluating the effectiveness and underlying mechanisms of patient education for people aged 50 and older who have osteoporosis or osteopenia. This randomized clinical trial compares three educational approaches to see how they affect osteoporosis self-care, quality of life, fracture risk, illness perception, physical activity, physical function, fear of falling, and pain. The study is sponsored by the University Hospital, Linkoeping, and aims to understand differences in outcomes among these education methods. Participants are randomly assigned to one of three groups a control group receiving standard osteoporosis information via an open website a face-to-face education group attending three 2-hour sessions led by physiotherapists and a physician or nurse over 2 months and a digital education group accessing nine online modules over one year. The digital program includes text, images, videos, exercises, and quizzes, with adherence tracked by module access, while attendance is recorded for face-to-face sessions. Participants complete questionnaires and physical tests at the start, and at 3 and 12 months follow-up. Some will also wear accelerometers to measure physical activity and sedentary behavior at these times. The main outcome measures include osteoporosis-specific self-care at 12 months, with additional assessments of health-related quality of life, fear of falling, illness perception, medication beliefs, physical activity, fracture risk, pain, balance, and physical performance. The study lasts at least one year with ongoing monitoring of participant progress.

This research aims to evaluate the effectiveness, lasting impact, and cost-effectiveness of the Safe Alternatives for Teens and Youth SAFETY intervention, a family-based cognitive-behavioral program designed to prevent suicide in youths aged 10 to 17 years who have recently attempted suicide. The study compares SAFETY to an enhanced version of usual treatment that includes safety planning. The goal is to see if SAFETY reduces subsequent suicide attempts and maintains these benefits up to 60 months after treatment. Participants will receive either the SAFETY intervention or Enhanced Treatment As Usual E-TAU. SAFETY is a 12-week program combining individual and family therapy sessions focused on building safety through safe settings, people, activities, thoughts, and stress reactions. E-TAU includes standard care plus an adapted safety planning intervention involving both youth and their caregivers. Both groups will have access to any required standard psychiatric treatments, including medication and inpatient care. During the study, youth and their caregivers will undergo assessments before treatment, immediately after, and at 3, 12, 24, and 60 months post-treatment. These evaluations include reports on suicide attempts, self-injury, mental health symptoms, functioning, and quality of life using standardized tools. Researchers will also collect data from medical and registry records to track psychiatric care, medication use, education, and employment. The study aims to understand how well SAFETY works, its long-term effects, and its economic value compared to usual care.